- Oligomycin A
-
- $68.00 / 1mg
-
2025-07-03
- CAS:579-13-5
- Min. Order:
- Purity: 99.89%
- Supply Ability: 10g
- OLIGOMYCIN A
-
- $1.00 / 100g
-
2019-12-23
- CAS:579-13-5
- Min. Order: 100g
- Purity: 99%
- Supply Ability: G/KG/T
|
| | OLIGOMYCIN A Basic information |
| Product Name: | OLIGOMYCIN A | | Synonyms: | OLIGOMYCIN A, STREPTOMYCES DIASTATOCHROMOGENES;OLIGOMYCIN A;OLIGOMYCIN, STREPTOMYCES DIASTATOCHROMOGENES;Oligomycin A fromStreptomyces diastatochromogenes;(1R,4E,5'S,6S,6'S,7R,8S,10R,11R,12S,14R,15S,16R,18E,20E,22R,25S,27R,28S,29R)-22-ethyl-7,11,14,15-tetrahydroxy-6'-[(2R)-2-hydroxypropyl]-5',6,8,10,12,14,16,28,29-nonamethyl-3',4',5',6'-tetrahydro-3H,9H,13H-spiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-pyran]-3,9,13-trione;(1R,4E,5'S,6S,6'S,7R,8S,10R,11R,12S,14R,15S,16R,18E,20E,22R,25S,27R,28S,29R)-22-ethyl-7,11,14,15-tetrahydroxy-6'-[(2R)-2-hydroxypropyl]-5',6,8,10,12,14,16,28,29-nonaMethyl-3',4',5',6'-tetrahydro-3H,9H,13H-spiro[2,26-dioxabicyclo[23.3.1]nonaco;MCH 32;AOligoMyci | | CAS: | 579-13-5 | | MF: | C45H74O11 | | MW: | 791.06 | | EINECS: | 209-437-3 | | Product Categories: | Inhibitors;antibiotic;Antibiotics;AntifungalAntibiotics;Antineoplastic and Immunosuppressive AntibioticsAntibiotics;Inhibits an EnzymeAntibiotics;Antibiotics A to;Antibiotics by Application;Antibiotics N-SAntibiotics;Chemical Structure Class;Macrolides;Mechanism of Action;Spectrum of Activity;API | | Mol File: | 579-13-5.mol |  |
| | OLIGOMYCIN A Chemical Properties |
| Melting point | 150-151℃ | | Boiling point | 886.3±65.0 °C(Predicted) | | density | 1.14 | | storage temp. | Sealed in dry,Store in freezer, under -20°C | | solubility | Soluble in DMSO, ethanol or acetone | | pka | 12.52±0.70(Predicted) | | form | powder | | color | white to off-white | | Merck | 13,6902 | | BRN | 5702132 | | InChIKey | MNULEGDCPYONBU-WMBHJXFZSA-N |
| | OLIGOMYCIN A Usage And Synthesis |
| Description | Oligomycins are macrolides created by Streptomyces species that can be toxic to other organisms. Different oligomycin isomers are highly specific for the disruption of mitochondrial metabolism. Oligomycin A, a dominant analog of the isomers, is an inhibitor of mitochondrial F1FO ATP synthase that induces apoptosis in a variety of cell types (average GI50 = 270 nM). Oligomycin A exhibits antifungal, antitumor, and nematocidal activities, but has poor solubility in water and other biocompatible solvents, which limits its clinical application. | | Chemical Properties | White powder | | Uses | Oligomycin A is the dominant analogue of a class of macrocyclic lactones isolated from selected strains of Streptomyces sp.. Oligomycin A is an inhibitor of mitochondrial F1F0-ATPase. It induces apoptosis in a variety of cell types, makes cells more susceptible to cell death, and also leads to a switch in the death mode from apoptosis to necrosis. Oligomycin A exhibits a broad biological profile including antifungal, antitumor and nematocidal activities. | | Uses | Oligomycin A is the dominant analogue of a class macrocyclic lactones isolated from selected strains of Streptomyces sp.. Oligomycin A is an inhibitor of mitochondrial F1F0-ATPase. It induces apoptosis in a variety of cell types, makes cells more susceptible to cell death, and also leads to a switch in the death mode from apoptosis to necrosis. Oligomycin A exhibits a broad biological profile including antifungal, antitumour and nematocidal activities. | | Uses | Oligomycin A is a macrolide with fungicidal activity isolated from Streptomyces species. | | storage | -20°C | | references | [1]. jastroch m, divakaruni as, mookerjee s, et al. mitochondrial proton and electron leaks. essays biochemistry, 2010, 47:53-67.
[2]. shchepina la, pletjushkina oy, avetisyan av, et al. oligomycin, inhibitor of the f-0 part of h+-atp-synthase, suppresses the tnf-induced apoptosis. oncogene, 2002, 53: 8149-8157.
[3]. salomon ar, voehringer dw, herzenberg la, et al. understanding and exploiting the mechanistic basis for selectivity of polyketide inhibitors of f0f1-atpase. proceedings of the national academy of sciences of the united states of america, 2000, 97(26): 14766-14771.
[4]. alexander r, adina v, ivan b, et al. overcoming intrinsic multi-drug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling jarid1bhigh cells. cancer cell, 2013, 23(6): 811-825. |
| | OLIGOMYCIN A Preparation Products And Raw materials |
|